Sulodexide for the Prevention of Recurrent Venous Thromboembolism | Zendy

Giuseppe Maria Andreozzi | Zendy; A Bignamini | Zendy; Giovanni Davı̀ | Zendy; Gualtiero Palareti | Zendy; Jiří Matuška | Zendy; Martin Holý | Zendy; Katarzyna Pawlaczyk-Gabriel | Zendy; Andrej Džupina | Zendy; German Sokurenko | Zendy; Yury P. Didenko | Zendy; Laurentia D. Andrei | Zendy; Gianfranco Lessiani | Zendy; Adriana Visonà | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sulodexide for the Prevention of Recurrent Venous Thromboembolism

Author(s) -

Giuseppe Maria Andreozzi,

A Bignamini,

Giovanni Davı̀,

Gualtiero Palareti,

Jiří Matuška,

Martin Holý,

Katarzyna Pawlaczyk-Gabriel,

Andrej Džupina,

German Sokurenko,

Yury P. Didenko,

Laurentia D. Andrei,

Gianfranco Lessiani,

Adriana Visonà

Publication year - 2015

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.115.016930

Subject(s) - medicine , discontinuation , hazard ratio , placebo , surgery , confidence interval , venous thrombosis , antithrombotic , anticoagulant , adverse effect , venous thromboembolism , thrombosis , alternative medicine , pathology

Patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after discontinuation of anticoagulant therapy. Extending anticoagulation reduces the risk of recurrence but is associated with increased bleeding. Sulodexide, a glycosaminoglycan, exerts antithrombotic and profibrinolytic actions with a low bleeding risk when administered orally, but its benefit for preventing recurrent venous thromboembolism is not well known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research